Pancreatic Cancer – Landscape & Forecast – Disease Landscape & Forecast

Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is less than 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and chemotherapies; thus, demand is high for safer, more-efficacious drugs. In the first line, FOLFIRINOX and Celgene’s Abraxane with gemcitabine therapy have emerged as alternative treatment strategies, while in the second line, Merrimack’s Onivyde appears to be a gaining traction. These therapies offer only modest survival benefits (overall survival is less than one year). Although current treatment is dominated by chemotherapies, upcoming targeted therapies, including AstraZeneca / Merck’s Lynparza, are expected to be better-tolerated options.

Questions answered:

  • What are the sizes of the U.S., EU5, and Japanese pancreatic cancer and PNET drug-treatable patient populations? How will drug-treatment rates change over our ten-year forecast period?
  • How are patients with pancreatic cancer and PNETs treated in the markets under study? What are interviewed experts’ insights on current treatment options?
  • What clinical needs remain unfulfilled, and which needs will be addressed by the end of our ten-year forecast period?
  • What are the key emerging therapies in development for pancreatic cancer and PNETs? What sales / uptake could these therapies secure in the pancreatic cancer market? What does the early-phase pipeline look like?

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Pancreatic Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • COVID-19
      • Key Findings
        • Pancreatic Cancer - Key Findings
      • Key Updates
        • October 2020
        • December 2019
        • August 2019
        • June 2019
      • Market Outlook
        • Key Findings
          • Market Share of Drug Classes for Pancreatic Cancer: 2018
          • Market Share of Drug Classes for Pancreatic Cancer: 2028
          • Drug-Treatable Population Share and Major-Market Sales Share in Pancreatic Cancer: 2018
          • Drug-Treatable Population Share and Major-Market Sales Share in Pancreatic Cancer: 2028
          • Pancreatic Cancer SWOT Analysis
        • COVID-19: Areas of Potential Forecast Impact
          • Market Drivers and Constraints
            • What Factors Are Driving the Market for Pancreatic Cancer?
            • What Factors Are Constraining the Market for Pancreatic Cancer?
            • Major-Market Sales of Key Therapies in the Pancreatic Cancer Market: 2018-2028
            • Major-Market Sales for Pancreatic Cancer, by Region: 2018-2028
            • Major-Market Sales for Pancreatic Cancer, by Population Segment: 2018-2028
          • Segment-Specific Trends
            • Key Regimens' Share of Major-Market Sales for First-Line Metastatic Pancreatic Cancer: 2018 vs. 2028
            • Key Regimens' Share of Major-Market Sales for Second-Line Metastatic Pancreatic Cancer: 2018 vs. 2028
        • Forecast
          • Market Forecast Assumptions - Pancreatic Cancer (2018-2028) - December 2019
          • Market Forecast Dashboard - Pancreatic Cancer (2018-2028) - December 2019
        • Etiology and Pathophysiology
          • Disease Overview
            • Tumor Invasion from the Head of the Pancreas into the Small Intestine
            • Common Metastatic Sites in Pancreatic Cancer
            • Etiology
            • Genetic Risk Factors for Developing Pancreatic Cancer
            • Nonmodifiable and Modifiable Risk Factors for Developing Pancreatic Cancer
            • Disease Pathophysiology of Pancreatic Adenocarcinoma
            • Development of Pancreatic Adenocarcinoma
            • Disease Pathophysiology of Pancreatic Neuroendocrine Tumors (PNETs)
            • Tumor, Node, Metastasis Status Staging System for Pancreatic Cancer
            • Stage Grouping System for Pancreatic Cancer
            • Grading System for Pancreatic Neuroendocrine Tumors (PNETs)
          • Key Pathways and Drug Targets
            • Signaling Pathways Implicated in the Development of Pancreatic Cancer
        • Epidemiology
          • Key Findings
            • Epidemiology Populations
              • Disease Definition
              • Methods
              • Sources Used for Diagnosed Incidence of Pancreatic Cancer
              • Number of Diagnosed Incident Cases of Pancreatic Cancer in the Major Pharmaceutical Markets by Subtype: 2018-2028
              • Disease Definition
              • Methods
              • Sources Used for Stage Distribution of Pancreatic Cancer
              • Number of Diagnosed Incident Cases of Pancreatic Exocrine Cancer in the Major Pharmaceutical Markets by Stage at Diagnosis: 2018-2028
              • Number of Diagnosed Incident Cases of Pancreatic Neuroendocrine Tumors in the Major Pharmaceutical Markets by Stage at Diagnosis: 2018-2028
              • Disease Definition
              • Methods
              • Sources Used for Recurrent Incidence of Pancreatic Cancer
              • Recurrent Incident Cases of Pancreatic Cancer: 2018-2028
              • Sources Used for Drug-Treatable Populations of Pancreatic Cancer
              • Pancreatic Exocrine Cancer Patient Flow
              • Pancreatic Neuroendocrine Tumors Patient Flow
              • Drug-Treatable Cases of Pancreatic Cancer: 2018-2028
              • Drug-Treated Cases of Pancreatic Cancer: 2018-2028
          • Current Treatment
            • Key Findings
              • Expert Insight
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for Pancreatic Cancer
            • Key Current Therapies
              • Overview
              • Mechanism of Action of Key Current Drugs or Drug Classes Used for Pancreatic Adenocarcinoma
              • Mechanism of Action of Key Current Drugs or Drug Classes Used for Pancreatic Neuroendocrine Tumors
              • Current Treatments Used for Pancreatic Adenocarcinoma
              • Current Treatments Used for Pancreatic Neuroendocrine Tumors
              • Market Events Impacting the Use of Key Current Therapies for Pancreatic Cancer
              • Advantages and Disadvantages of Abraxane
              • Key Results from Select Clinical Trials Investigating Abraxane for the Treatment of Pancreatic Adenocarcinoma
              • Ongoing Clinical Development of Abraxane
              • Expert Insight: Abraxane
              • Advantages and Disadvantages of Onivyde
              • Key Results from Select Clinical Trials Investigating Onivyde for the Treatment of Pancreatic Adenocarcinoma
              • Ongoing Clinical Development of Onivyde
              • Key Ongoing Clinical Trials of Onivyde in the Treatment of Pancreatic Adenocarcinoma
              • Expert Insight: Onivyde
              • Advantages and Disadvantages of Tarceva
              • Ongoing Clinical Development of Tarceva
              • Key Ongoing Clinical Trials of Tarceva in the Treatment of Pancreatic Adenocarcinoma
              • Expert Insight: Tarceva
              • Advantages and Disadvantages of Keytruda
              • Key Results from Select Clinical Trials Investigating Keytruda for the Treatment of Pancreatic Cancer
              • Ongoing Clinical Development of Keytruda
              • Key Ongoing Clinical Trials of Keytruda in the Treatment of Pancreatic Cancer
              • Expert Insight: Keytruda
              • Key Results of Select Clinical Trials Investigating Lynparza for the Treatment of Pancreatic Adenocarcinoma
              • Ongoing Clinical Development of Lynparza
              • Key Ongoing Clinical Trials of Lynparza in the Treatment of Pancreatic Cancer
              • Expert Insight: Lynparza
              • Advantages and Disadvantages of Somatuline Autogel/Depot
              • Ongoing Clinical Development of Somatuline Autogel/Depot
              • Expert Insight: Somatuline Autogel/Depot
              • Advantages and Disadvantages of Lutathera
              • Key Results from Select Clinical Trials Investigating Lutathera for the Treatment of Pancreatic Neuroendocrine Tumors
              • Ongoing Clinical Development of Lutathera
              • Expert Insight: Lutathera
              • Advantages and Disadvantages of Afinitor
              • Ongoing Clinical Development of Afinitor
              • Key Ongoing Clinical Trials of Afinitor in the Treatment of Pancreatic Neuroendocrine Tumors
              • Expert Insight: Afinitor
              • Advantages and Disadvantages of Sutent
              • Expert Insight: Sutent
            • Medical Practice
              • Pancreatic Cancer: Resectable (Stage I-IIB)
              • Pancreatic Cancer: Unresectable (Stage III) and Metastatic (Stage IV), First-Line
              • Pancreatic Cancer: Metastatic, Second-Line
              • Pancreatic Neuroendocrine Tumors: Resectable (Stage I-II)
              • Pancreatic Neuroendocrine Tumors: Unresectable (Stage III) and Metastatic (Stage IV), First-Line
              • Pancreatic Neuroendocrine Tumors: Metastatic, Second-Line
              • Pancreatic Adenocarcinoma Treatment Guidelines
              • Pancreatic Neuroendocrine Tumors Treatment Guidelines
              • Patient Characteristics Influencing Drug Selection in Pancreatic Cancer
              • Treatment Decision Tree for Pancreatic Adenocarcinoma: United States
              • Treatment Decision Tree for Pancreatic Neuroendocrine Tumors: United States
              • Treatment Decision Tree for Pancreatic Adenocarcinoma: Europe
              • Treatment Decision Tree for Pancreatic Neuroendocrine Tumors: Europe
              • Treatment Decision Tree for Pancreatic Adenocarcinoma: Japan
              • Treatment Decision Tree for Pancreatic Neuroendocrine Tumors: Japan
          • Unmet Need
            • Current and Future Attainment of Unmet Needs in Pancreatic Cancer
            • Expert Insight on Unmet Needs in the Treatment of Pancreatic Cancer
            • Top Unmet Needs in the Treatment of Pancreatic Canceru2014Current and Future Attainment
          • Emerging Therapies
            • Key Findings
              • Pipeline Trends in Pancreatic Cancer
            • Key Emerging Therapies
              • Notable Developments Among Key Emerging Therapies for Pancreatic Cancer
              • Key Therapies in Development for Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Glufosfamide for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Glufosfamide in the Treatment of Pancreatic Cancer
              • Analysis of the Clinical Development Program for Glufosfamide
              • Expert Insight: Glufosfamide
              • Expectations for Market Authorization and Sales Opportunity for Glufosfamide in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Masiviera for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Masiviera in the Treatment of Pancreatic Cancer
              • Analysis of the Clinical Development Program for Masiviera
              • Expert Insight: Masiviera
              • Expectations for Market Authorization and Sales Opportunity of Masiviera in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Vaccell for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Vaccell in the Treatment of Pancreatic Cancer
              • Expert Insight: Use of Vaccell in the Treatment of Pancreatic Cancer
              • Expert Insight: Vaccell
              • Expectations for Market Authorization and Sales Opportunity for Vaccell in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Pamrevlumab for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Pamrevlumab in the Treatment of Pancreatic Cancer
              • Analysis of the Clinical Development Program for Pamrevlumab
              • Expert Insight: Pamrevlumab
              • Expectations for Market Authorization and Sales Opportunity of Pamrevlumab in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Nanoplatin for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Nanoplatin in the Treatment of Pancreatic Cancer
              • Nanoplatin Clinical Development
              • Expert Insight: Use of Nanoplatin in the Treatment of Pancreatic Cancer
              • Expectations for Market Authorization and Sales Opportunity for Nanoplatin in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Devimistat for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Devimistat in the Treatment of Pancreatic Cancer
              • Analysis of the Clinical Development Program for Devimistat (CPI-613)
              • Expert Insight: Devimistat (CPI-613)
              • Expectations for Market Authorization and Sales Opportunity for Devimistat in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Eryaspase for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Eryaspase in the Treatment of Pancreatic Cancer
              • Analysis of the Clinical Development Program for Eryaspase (GRASPA)
              • Expert Insight: Eryaspase (GRASPA)
              • Expectations for Market Authorization and Sales Opportunity of Eryaspase in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating SM-88 (Racemetyrosine) for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of SM-88 (Racemetyrosine) in the Treatment of Pancreatic Cancer
              • Analysis of the Clinical Development Program for SM-88 (Racemetyrosine)
              • Expert Insight: SM-88 (Racemetyrosine)
              • Expectations for Market Authorization and Sales Opportunity of SM-88 (Racemetyrosine) in Pancreatic Cancer
            • Early-Phase Pipeline Analysis
              • Select Compounds in Early-Phase Development for Pancreatic Cancer
            • Key Discontinuations and Failures in Pancreatic Cancer
              • Key Discontinuations and Failures
          • Access & Reimbursement
            • Region-Specific Reimbursement Practices
              • Key Market Access Considerations in Pancreatic Cancer: United States
              • General Reimbursement Environment: United States
              • Key Market Access Considerations in Pancreatic Cancer: EU5
              • General Reimbursement Environment: EU5
              • Key Market Access Considerations in Pancreatic Cancer: Japan
              • General Reimbursement Environment: Japan
            • Looking for More?
          • Appendix
            • Key Abbreviations Related to Pancreatic Cancer
            • Brands, Marketers, and Generic Availability of Key Therapies for Pancreatic Cancer, by Market
            • Pancreatic Cancer Bibliography